Differential modulation of a 40 kDa catecholamine regulated protein in the core and shell subcompartments of the nucleus accumbens following chronic quinpirole and haloperidol administration in the rat

Synapse

Volumn 61, Issue 10, 2007, Pages 835-842

  Gabriele, Joseph ^a   Thomas, Nancy ^a   N Marandi, Sevil ^a   Mishra, Ram ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Catecholamine regulated protein; Dopamine; Nucleus accumbens

Indexed keywords

CATECHOLAMINE; CATECHOLAMINE REGULATED PROTEIN; HALOPERIDOL; HEAT SHOCK PROTEIN 70; PROTEIN S 100; QUINPIROLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DRUG EFFECT; IN VIVO STUDY; MALE; NEUROCHEMISTRY; NONHUMAN; NUCLEUS ACCUMBENS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RAT; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DRUG ADMINISTRATION SCHEDULE; GENE EXPRESSION REGULATION; HALOPERIDOL; HSP70 HEAT-SHOCK PROTEINS; MALE; NERVE TISSUE PROTEINS; NUCLEUS ACCUMBENS; QUINPIROLE; RATS; RATS, LONG-EVANS;

EID: 34548224187     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20435     Document Type: Article

References (61)

1. Akil M, Pierri JN, Whitehead RE, Edgar CL, Mohila C, Sampson AR, Lewis DA. 1999. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry 156:1580-1589.
2. Banks KE, Gratton A. 1995. Possible involvement of medial prefrontal cortex in amphetamine-induced sensitization of mesolimbic dopamine function. Eur J Pharmacol 282:157-167.
3. Bardo MT, Hammer RP Jr. 1991. Autoradiographic localization of dopamine D1 and D2 receptors in rat nucleus accumbens: Resistance to differential rearing conditions. Neuroscience 45:281-290.
4. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
5. Brundege JM, Williams JT. 2002. Differential modulation of nucleus accumbens synapses. J Neurophysiol 88:142-151.
6. Cadet JL, Brannock C. 1998. Free radicals and the pathobiology of brain dopamine systems. Neurochem Int 32:117-131.
7. Canales JJ, Iversen SD. 2000. Dynamic dopamine receptor interactions in the core and shell of nucleus accumbens differentially coordinate the expression of unconditioned motor behaviors. Synapse 36:297-306.
8. Chergui K, Lacey MG. 1999. Modulation by dopamine D1-like receptors of synaptic transmission and NMDA receptors in rat nucleus accumbens is attenuated by the protein kinase C inhibitor Ro 32-0432. Neuropharmacology 38:223-231.
9. Chiueh CC, Miyake H, Peng MT. 1993. Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism. Adv Neurol 60:251-258.
10. Deutch AY. 1992. The regulation of subcortical dopamine systems by the prefrontal cortex: Interactions of central dopamine systems and the pathogenesis of schizophrenia. J Neural Transm Suppl 36:61-89.
11. Dreher JK, Jackson DM. 1989. Role of D1 and D2 dopamine receptors in mediating locomotor activity elicited from the nucleus accumbens of rats. Brain Res 487:267-277.
12. Eilam D, Szechtman H. 1989. Biphasic effect of D-2 agonist quinpirole on locomotion and movements. Eur J Pharmacol 161:151-157.
13. Gabriele J, Rajaram M, Zhang B, Sharma S, Mishra RK. 2002. Modulation of a 40-kDa catecholamine-regulated protein following D-amphetamine treatment in discrete brain regions. Eur J Pharmacol 453:13-19.
14. Gabriele J, Culver K, Sharma S, Zhang B, Szechtman H, Mishra R. 2003. Asymmetric modulation of a catecholamine-regulated protein in the rat brain, following quinpirole administration. Synapse 49:261-269.
15. Gabriele JP, Mishra R.K. 2007. Catecholamine regulated protein (CRP40) as a possible blood biomarker in schizophrenia. International Congress on Schizophrenia Research Colorado Springs, CO. p 305.
16. Gabriele JP, Thomas NR, Thomson CA, Pristupa ZB, Chong VZ, Mishra RK. 2004. Cloning of a human catecholamine regulator protein. Federation of American Societies for Experimental Biology, Washington, DC, No. 6948.
17. Gabriele JP, Chong VZ, Pontoriero GF, Mishra RK. 2005. Decreased expression of a 40-kDa catecholamine-regulated protein in the ventral striatum of schizophrenic brain specimens from the Stanley Foundation Neuropathology Consortium. Schizophr Res 74:111-119.
18. Goto A, Doering L, Nair VD, Mishra RK. 2001. Immunohistochemical localization of a 40-kDa catecholamine regulated protein in the nigrostriatal pathway. Brain Res 900:314-319.
19. Groenewegen HJ, Wright CI, Beijer AV, Voorn P. 1999. Convergence and segregation of ventral striatal inputs and outputs. Ann NY Acad Sci 877:49-63.
20. Hastings TG, Zigmond MJ. 1994. Identification of catechol-protein conjugates in neostriatal slices incubated with [3H] dopamine: Impact of ascorbic acid and glutathione. J Neurochem 63:1126-1132.
21. Kalivas PW, Stewart J. 1991. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Brain Res Rev 16:223-244.
22. King D, Finlay JM. 1997. Loss of dopamine terminals in the medial prefrontal cortex increased the ratio of DOPAC to DA in tissue of the nucleus accumbens shell: Role of stress. Brain Res 767:192-200.
23. King D, Zigmond MJ, Finlay JM. 1997. Effects of dopamine depletion in the medial prefrontal cortex on the stress-induced increase in extracellular dopamine in the nucleus accumbens core and shell. Neuroscience 77:141-153.
24. Macario AJ, Conway dM. 2002. Sick chaperones and ageing: A perspective. Ageing Res Rev 1:295-311.
25. Marcus MM, Nomikos GG, Svensson TH. 1996. Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens. Eur Neuropsychopharmacol 6:29-38.
26. Marcus MM, Malmerfelt A, Nyberg S, Svensson TH. 2002. Biochemical effects in brain of low doses of haloperidol are qualitatively similar to those of high doses. Eur Neuropsychopharmacol 12:379-386.
27. Maurice N, Deniau JM, Glowinski J, Thierry AM. 1998a. Relationships between the prefrontal cortex and the basal ganglia in the rat: Physiology of the corticosubthalamic circuits. J Neurosci 18:9539-9546.
28. Maurice N, Deniau JM, Menetrey A, Glowinski J, Thierry AM. 1998b. Prefrontal cortex-basal ganglia circuits in the rat: Involvement of ventral pallidum and subthalamic nucleus. Synapse 29:363-370.
29. Meredith GE. 1999. The synaptic framework for chemical signaling in nucleus accumbens. Ann NY Acad Sci 877:140-156.
30. Meredith GE, De Souza IE, Hyde TM, Tipper G, Wong ML, Egan MF. 2000. Persistent alterations in dendrites, spines, and dynorphinergic synapses in the nucleus accumbens shell of rats with neuroleptic-induced dyskinesias. J Neurosci 20:7798-7806.
31. Mitchell JB, Gratton A. 1992. Partial dopamine depletion of the prefrontal cortex leads to enhanced mesolimbic dopamine release elicited by repeated exposure to naturally reinforcing stimuli. J Neurosci 12:3609-3618.
32. Modi PI, Kashyap A, Nair VD, Ross GM, Fu M, Savelli JE, Marcotte ER, Barlas C, Mishra RK. 1996. Modulation of brain catecholamine absorbing proteins by dopaminergic agents. Eur J Pharmacol 299:213-220.
33. Muchowski PJ. 2002. Protein misfolding, amyloid formation, and neurodegeneration: A critical role for molecular chaperones? Neuron 35:9-12.
34. Nair VD, Mishra RK. 2001. Molecular cloning, localization and characterization of a 40-kDa catecholamine-regulated protein. J Neurochem 76:1142-1152.
35. Olanow CW, Tatton WG. 1999. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 22:123-144.
36. Olanow CW, Jenner P, Brooks D. 1998. Dopamine agonists and neuroprotection in Parkinson's disease. Ann Neurol 44:S167-S174.
37. Owen MJ. 2005. Genomic approaches to schizophrenia. Clin Ther 27(Suppl A):S2-S7.
38. Peuskens J, Demily C, Thibaut F. 2005. Treatment of cognitive dysfunction in schizophrenia. Clin Ther 27(Suppl A):S25-S37.
39. Pycock CJ, Kerwin RW, Carter CJ. 1980. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature 286:74-76.
40. Qing H, Xu H, Wei Z, Gibson K, Li XM. 2003. The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+-induced apoptosis. Eur J Neurosci 17:1563-1570.
41. Reddy RD, Yao JK. 1996. Free radical pathology in schizophrenia: A review. Prostaglandins Leukot Essent Fatty Acids 55:33-43.
42. Robinson TE, Becker JB. 1986. Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis. Brain Res 396:157-198.
43. Ross GM, McCarry BE, Thakur S, Mishra RK. 1993. Identification of novel catecholamine absorbing proteins in the central nervous system. J Mol Neurosci 4:141-148.
44. Ross GM, McCarry BE, Mishra RK. 1995. Covalent affinity labeling of brain catecholamine-absorbing proteins using a high-specific-activity substituted tetrahydronaphthalene. J Neurochem 65: 2783-2789.
45. Rotrosen J, Adler L, Lohr J, Edson R, Lavori P. 1996. Antioxidant treatment of tardive dyskinesia. Prostaglandins Leukot Essent Fatty Acids 55:77-81.
46. Schmidt HD, Anderson SM, Pierce RC. 2006. Stimulation of D1-like or D2 dopamine receptors in the shell, but not the core, of the nucleus accumbens reinstates cocaine-seeking behaviour in the rat. Eur J Neurosci 23:219-228.
47. Sellings LH, Clarke PB. 2006. 6-Hydroxydopamine lesions of nucleus accumbens core abolish amphetamine-induced conditioned activity. Synapse 59:374-377.
48. Sharan N, Nair VD, Mishra RK. 2001. Modulation of a 40-kDa catecholamine regulated protein by dopamine receptor antagonists. Eur J Pharmacol 413:73-79.
49. Sharan N, Chong VZ, Nair VD, Mishra RK, Hayes RJ, Gardner EL. 2003. Cocaine treatment increases expression of a 40 kDa catecholamine-regulated protein in discrete brain regions. Synapse 47:33-44.
50. Simonian NA, Coyle JT. 1996. Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol 36:83-106.
51. Subramaniam S, Lucki I, McGonigle P. 1992. Effects of chronic treatment with selective agonists on the subtypes of dopamine receptors. Brain Res 571:313-322.
52. Subramaniam S, Marcotte ER, Srivastava LK. 2001. Differential changes in synaptic terminal protein expression between nucleus accumbens core and shell in the amphetamine-sensitized rat. Brain Res 901:175-183.
53. Szechtman H, Dai H, Mustafa S, Einat H, Sullivan RM. 1994a. Effects of dose and interdose interval on locomotor sensitization to the dopamine agonist quinpirole. Pharmacol Biochem Behav 48:921-928.
54. Szechtman H, Talangbayan H, Canaran G, Dai H, Eilam D. 1994b. Dynamics of behavioral sensitization induced by the dopamine agonist quinpirole and a proposed central energy control mechanism. Psychopharmacology (Berl) 115:95-104.
55. Szumlinski KK, Allan M, Talangbayan H, Tracey A, Szechtman H. 1997. Locomotor sensitization to quinpirole: Environment-modulated increase in efficacy and context-dependent increase in potency. Psychopharmacology (Berl) 134:193-200.
56. Walters JR, Bergstrom DA, Carlson JH, Chase TN, Braun AR. 1987. Dl dopamine receptor activation required for postsynaptic expression of D2 agonist effects. Science 236:719-722.
57. Weinberger DR. 1987. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44:660-669.
58. Wieczorek W, Kruk ZL. 1995. Influences of neuronal uptake and D2 autoreceptors on regulation of extracellular dopamine in the core, shell and rostral pole of the rat nucleus accumbens. Brain Res 699:171-182.
59. Zahm DS. 1999. Functional-anatomical implications of the nucleus accumbens core and shell subterritories. Ann NY Acad Sci 877:113-128.
60. Zahm DS. 2000. An integrative neuroanatomical perspective on some subcortical substrates of adaptive responding with emphasis on the nucleus accumbens. Neurosci Biobehav Rev 24:85-105.
61. Zahm DS, Jensen SL, Williams ES, Martin JR III. 1999. Direct comparison of projections from the central amygdaloid region and nucleus accumbens shell. Eur J Neurosci 11:1119-1126.